Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.39 |
| ▸ | IRAK2 | O43187 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.37 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 3/20 | 0.35 |
| ▸ | HTR1B | P28222 | 3/20 | 0.35 |
| ▸ | HTR1F | P30939 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23536638 | 0.76 | PDE10A (0.42) | HTR1DHTR1BHTR1FHTR1APDE10A | |
| SCHEMBL2467357 | 0.73 | HSD11B1 (0.44) | IRAK4RPS6KA3CYP2D6 | |
| SCHEMBL19972617 | 0.69 | GPR119 (0.47) | HTR1DHTR1BHTR1FHTR1APDE10A | |
| SCHEMBL30451058 | 0.66 | DAO (0.37) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL26912470 | 0.66 | PRKDC (0.47) | HTR1DHTR1BHTR1FHTR1AJAK2 | |
| SCHEMBL31164574 | 0.64 | JAK2 (0.41) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL28103741 | 0.64 | GRM4 (0.36) | — | |
| SCHEMBL2619212 | 0.64 | PIM1 (0.34) | — | |
| SCHEMBL4067918 | 0.64 | MAPK1 (0.41) | HASPIN | |
| SCHEMBL8820853 | 0.64 | AURKA (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | disclosed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | disclosed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | disclosed |
| EP-2927233-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | Proximagen Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| EP-2927233-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | Proximagen Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| EP-2547677-B1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | PROXIMAGEN LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| EP-2547677-B1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | PROXIMAGEN LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | PROXIMAGEN LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | PROXIMAGEN LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | PROXIMAGEN LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| EP-2547677-A2 | INHIBITORS OF SEMICARABAZIDE - SENSITIVE AMINE OXIDASE | Proximagen Limited (GB) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113798-A2 | NEW ENZYME INHIBITOR COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | SERPINB1, SSB, NFKBIA | IRAK4 3200/4885IRAK2 3020/4885CLK1 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.